Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
INVA Stock Forecast 2026-2027
$23.60
Current Price
$1.81B
Market Cap
Buy 4
Hold 0
Sell 1
Wall St Analyst Ratings
Distance to INVA Price Targets
+94.9%
To High Target of $46.00
+48.3%
To Median Target of $35.00
-23.7%
To Low Target of $18.00
INVA Price Momentum
-0.7%
1 Week Change
+7.8%
1 Month Change
+29.2%
1 Year Change
+18.1%
Year-to-Date Change
-6.2%
From 52W High of $25.15
+42.9%
From 52W Low of $16.52
📊 TOP ANALYST CALLS
Did INVA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Innoviva is one of their latest high-conviction picks.
Latest INVA Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, INVA has a bullish consensus with a median price target of $35.00 (ranging from $18.00 to $46.00). The overall analyst rating is Strong Buy (8.4/10). Currently trading at $23.60, the median forecast implies a 48.3% upside. This outlook is supported by 4 Buy, 0 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Raghuram Selvaraju at HC Wainwright & Co., projecting a 94.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INVA Analyst Ratings
4
Buy
0
Hold
1
Sell
INVA Price Target Range
Low
$18.00
Average
$35.00
High
$46.00
Current: $23.60
Latest INVA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INVA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 26, 2026 | BTIG | Julian Harrison | Buy | Reiterates | $35.00 |
| Feb 17, 2026 | BTIG | Julian Harrison | Buy | Initiates | $35.00 |
| Dec 16, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $46.00 |
| Nov 6, 2025 | Cantor Fitzgerald | Steve Seedhouse | Overweight | Maintains | $31.00 |
| Sep 30, 2025 | Goldman Sachs | Asad Haider | Sell | Initiates | $17.00 |
| Aug 11, 2025 | Oppenheimer | Trevor Allred | Outperform | Initiates | $35.00 |
| Aug 11, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $45.00 |
| Jul 14, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Initiates | $40.00 |
| Jul 11, 2025 | Cantor Fitzgerald | Steve Seedhouse | Overweight | Initiates | $26.00 |
| Mar 7, 2025 | Scotiabank | Louise Chen | Sector Outperform | Initiates | $55.00 |
| Aug 1, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $N/A |
| Jul 30, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $N/A |
| Jun 20, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $N/A |
| Jun 18, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Initiates | $N/A |
| May 10, 2023 | EF Hutton | Constantine Davides | Buy | Reiterates | $22.50 |
| Apr 20, 2023 | EF Hutton | Constantine Davides | Buy | Reiterates | $22.50 |
| Mar 3, 2023 | Morgan Stanley | Matthew Harrison | Underweight | Maintains | $10.00 |
| Mar 3, 2023 | Goldman Sachs | Chris Shibutani | Neutral | Maintains | $13.00 |
| Mar 3, 2023 | EF Hutton | Constantine Davides | Buy | Reiterates | $22.50 |
| Jan 24, 2023 | Morgan Stanley | Matthew Harrison | Underweight | Maintains | $13.00 |
Innoviva Inc. (INVA) Competitors
The following stocks are similar to Innoviva based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Innoviva Inc. (INVA) Financial Data
Innoviva Inc. has a market capitalization of $1.81B with a P/E ratio of 7.2x. The company generates $411.33M in trailing twelve-month revenue with a 65.9% profit margin.
Revenue growth is +24.8% quarter-over-quarter, while maintaining an operating margin of +34.7% and return on equity of +29.1%.
Valuation Metrics
Market Cap
$1.81B
Enterprise Value
$1.54B
P/E Ratio
7.2x
PEG Ratio
0.0x
Price/Sales
4.3x
Growth & Margins
Revenue Growth (YoY)
+24.8%
Gross Margin
+88.9%
Operating Margin
+34.7%
Net Margin
+65.9%
EPS Growth
+707.4%
Financial Health
Cash/Price Ratio
+32.4%
Current Ratio
14.6x
Debt/Equity
28.2x
ROE
+29.1%
ROA
+7.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Innoviva Inc. (INVA) Business Model
About Innoviva Inc.
What They Do
Pharmaceutical company managing royalty portfolios.
Business Model
Innoviva Inc. generates revenue by managing royalty portfolios from collaborations with pharmaceutical partners. The company focuses on optimizing the value of its intellectual property and strategic partnerships to maximize returns from its investments in respiratory disease treatments, particularly for COPD and asthma.
Additional Information
Founded in 1996 as Theravance, Innoviva shifted its focus to royalty management and biopharmaceutical investments. This strategic positioning enhances its influence in the respiratory disease market and contributes to advancements in healthcare.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
159
CEO
Mr. Pavel Raifeld C.F.A.
Country
United States
IPO Year
2004
Website
www.inva.comInnoviva Inc. (INVA) Latest News & Analysis
Latest News
Quick Summary
The average P/E ratio for S&P 500 stocks is approximately 27X, indicating the valuation of companies within this index.
Why It Matters
A P/E ratio of 27X for S&P 500 stocks indicates high valuations, suggesting potential overvaluation or growth expectations, impacting investment decisions and market sentiment.
Source: MarketBeat
Market Sentiment:
Positive
Quick Summary
A drug stock is leveraging recent declines to establish a bullish base, with analysts forecasting significant price increases in the near future.
Why It Matters
The drug stock's bullish base indicates potential for future price appreciation, suggesting a favorable investment opportunity driven by analyst optimism.
Source: Investors Business Daily
Market Sentiment:
Positive
Quick Summary
Innoviva Specialty Therapeutics received an 80% rating in the 2026 Antimicrobial Resistance Benchmark Report, the highest for SMEs, alongside one other company.
Why It Matters
Innoviva Specialty Therapeutics' high rating in the AMR Benchmark enhances its reputation, potentially attracting investment and boosting stock prices due to increased confidence in its therapeutics portfolio.
Source: Business Wire
Market Sentiment:
Neutral
Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress
1 month ago
Quick Summary
Innoviva, Inc. (NASDAQ: INVA) reported its Q4 and full-year financial results for 2025, showcasing progress in its biopharmaceutical operations and portfolio developments.
Why It Matters
Innoviva's reported financial results and corporate progress signal potential growth and profitability, influencing investor confidence and stock performance in the biopharmaceutical sector.
Source: Business Wire
Market Sentiment:
Neutral
Innoviva, Inc. (INVA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
1 month ago
Quick Summary
Innoviva, Inc. (INVA) presented at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, highlighting its latest developments and strategies.
Why It Matters
Innoviva's presentation at a prominent healthcare conference could signal new developments or strategies, impacting investor sentiment and stock performance in the biopharma sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
1 month ago
Quick Summary
Innoviva, Inc. (NASDAQ: INVA) will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026.
Why It Matters
Innoviva's participation in a major healthcare conference can signal potential growth opportunities and investor interest, impacting stock performance and market perception.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About INVA Stock
What is Innoviva Inc.'s (INVA) stock forecast for 2026?
Based on our analysis of 11 Wall Street analysts, Innoviva Inc. (INVA) has a median price target of $35.00. The highest price target is $46.00 and the lowest is $18.00.
Is INVA stock a good investment in 2026?
According to current analyst ratings, INVA has 4 Buy ratings, 0 Hold ratings, and 1 Sell ratings. The stock is currently trading at $23.60. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for INVA stock?
Wall Street analysts predict INVA stock could reach $35.00 in the next 12 months. This represents a 48.3% increase from the current price of $23.60. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Innoviva Inc.'s business model?
Innoviva Inc. generates revenue by managing royalty portfolios from collaborations with pharmaceutical partners. The company focuses on optimizing the value of its intellectual property and strategic partnerships to maximize returns from its investments in respiratory disease treatments, particularly for COPD and asthma.
What is the highest forecasted price for INVA Innoviva Inc.?
The highest price target for INVA is $46.00 from Raghuram Selvaraju at HC Wainwright & Co., which represents a 94.9% increase from the current price of $23.60.
What is the lowest forecasted price for INVA Innoviva Inc.?
The lowest price target for INVA is $18.00 from at , which represents a -23.7% decrease from the current price of $23.60.
What is the overall INVA consensus from analysts for Innoviva Inc.?
The overall analyst consensus for INVA is bullish. Out of 11 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 1 as Sell, with a median price target of $35.00.
How accurate are INVA stock price projections?
Stock price projections, including those for Innoviva Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 17, 2026 9:09 PM UTC